OCLN Cancer Research Results

OCLN, Occludin: Click to Expand ⟱
Source:
Type:
Occludin 
Target/Pathway: Occludin
Abbreviation: OCLN
Category: Tight junction / intestinal barrier
Direction in IBD: usually down
Cancer relevance: usually barrier-loss associated, especially in inflammation-linked colorectal cancer


Scientific Papers found: Click to Expand⟱
5932- CAR,    Carvacrol attenuates mucosal barrier impairment and tumorigenesis by regulating gut microbiome
- in-vivo, IBD, NA - in-vivo, Park, NA
*GutMicro↑, Carvacrol can regulate the gut microbiota. bundance of specific microbiota, such as Lactobacillus, Escherichia coli/Shigella, and Lachnoclostridium.
Risk↓, Carvacrol inhibits the development of colitis-associated colorectal cancer.
*Inflam↓, nti-inflammatory and antioxidant traits,
*antiOx↓,
*ZO-1↑, carvacrol significantly restored colonic length (p < 0.01) and re-established key tight junction proteins like ZO-1.
*iNOS↓, downregulated mRNA levels of inflammatory mediators such as iNOS and IL-6.
*IL6↓,
*NO↓, carvacrol has been shown to suppress nitric oxide and prostaglandin E2 production
*PGE2↓,
*memory↑, carvacrol improves memory deficits in Parkinson’s disease models
*TLR4↓, anti-inflammatory effects of carvacrol by inhibiting the TLR4/NF-κB signaling pathway
*NF-kB↓,
*IBI↑, Carvacrol improves intestinal barrier function
*CLDN3↑, expression levels of ZO-1, Claudin3, Claudin1, Occludin, and Mucin were significantly increased in the carvacrol group compared to the DSS group
*CLDN1↑,
*MUC1↑,
*OCLN↑,
*iNOS↑, carvacrol significantly inhibited the mRNA expression levels of iNOS, COX-2, Interferon-γ, IL-1β, and IL-6 in the intestinal tracts of colitis mice
*COX2/PTGS2↓,
*IFN-γ↓,
IL1β↓,
ADAM10?,

7429- CS,    Functional and Therapeutic Potential of Cynara scolymus in Health Benefits
- Review, Nor, NA - Review, IBD, NA - Review, AD, NA
*Inflam↓, C. scolymus exhibits anti-inflammatory, antioxidant, liver-protective, bile-expelling, antimicrobial, and lipid-lowering neuroprotective properties.
*antiOx↑, Of particular interest is the abundance of chlorogenic acid, a type of caffeoylquinic acid known also by its antioxidant activity.
*hepatoP↑,
*lipid-P↓,
*TNF-α↓, Pectins from artichoke reduced the expression of inflammatory markers such as TNF-α, ICAM-I, IL-1β, and IL-6 in mice. This has resulted in a decrease in iNOS and TLR4 expression in favor of reducing inflammation.
*ICAM-1↓,
*IL1β↓,
*IL6↓,
*MUC1↑, artichoke pectin increased the intestinal barrier genes expression, MUC-1 and Occludin.
*OCLN↑,
*IBI↑, artichoke pectin has the potential to improve IBD by inhibiting inflammation and promoting the expression of genes involved in intestinal barrier function
*ROS↓, The beneficial components derived from artichoke have shown important scavenging activity against reactive oxygen species (ROS) and free radicals.
*cardioP↑, Moreover, artichoke leaf extracts supplementation has also decreased the cardiac markers and increased the antioxidant enzyme SOD, GPx, and GSH activities [80].
*SOD↑,
*GPx↑,
*GSH↑,
*TG/TAG↓, resulting in lower triglyceride (TG) levels
*LDL↓, 8 weeks with artichoke leaf extracts (administered as two daily doses of 250 mg). This treatment significantly reduced total cholesterol (TC), LDL cholesterol (LDL-c),
*neuroP↑, Growing evidence highlights the neuroprotective role of polyphenols
*5HT↑, Polyphenols have been shown to improve mood by increasing serotonin levels in the brain, stimulating the production of brain-derived neurotrophic factor (BDNF), and reducing inflammation
*BDNF↑,

7006- Fuc,    Seaweeds in the Oncology Arena: Anti-Cancer Potential of Fucoidan as a Drug—A Review
- Review, Var, NA
*toxicity↓, Fucoidan is a versatile, nontoxic marine-origin heteropolysaccharide that has received much attention due to its beneficial biological properties and safety.
*AntiViral↑, ucoidan has been demonstrated to exhibit a variety of conventional bioactivities, such as antiviral, antioxidant, and immune-modulatory characteristics, and anticancer activity against a wide range of malignancies has also recently been discovered.
*antiOx↑,
*Imm⇅,
AntiCan↑,
TumCCA↑, Fucoidan inhibits tumorigenesis by prompting cell cycle arrest and apoptosis, blocking metastasis and angiogenesis, and modulating physiological signaling molecules.
Apoptosis↑,
TumMeta↓,
angioG↓,
antiNeop↑, Fucoidans’ capacity to bind to Toll-like receptors and intervene with the action of vascular endothelial growth factors (VEGF) and matrix metalloproteinases (MMPs) could explain their anti-neoplastic properties
VEGF↓,
MMPs↓,
BioAv↑, Low molecular weight fractions (LMWF), in particular, are thought to be more biocompatible [47]
BioAv↑, in rats, following topical administration of fucoidan (MW 750 kDa) from Fucus vesiculosus demonstrated fine skin-penetrating characteristics.
ROS⇅, Induction/inhibition of reactive oxygen species (ROS), mitochondrial instability, and caspase and poly (ADP-ribose) polymerase (PARP) cleavage are all aspects of it
cl‑PARP↑, fucoidan treatment causes PARP cleavage and caspase-3/7 activation in MCF-7 cells, which are hallmarks of apoptosis [
Casp3↑,
Casp7↑,
ROS↑, human hepatoma SMMC-7721 cells, fucoidan therapy caused noteworthy growth inhibition and ROS-mediated apoptosi
GSH↓, lower glutathione consumption (GSH), mitochondrial swelling, and depolarization of the mitochondrial membrane potential
MMP↓,
PI3K↓, Fucoidan inhibits PI3K, suppressing ERK and activates MAPK, limiting cancer cell proliferation and decreasing Bcl-2 to Bax ratio, inducing caspase-dependent apoptosis in BEL-7402 and LM3 cell lines
ERK↓,
MAPK↑,
TumCP↓,
Bax:Bcl2↑,
TJ↑, Meanwhile, dietary fucoidan progressively restores intestinal villi by upregulating the expression of tight junction proteins such as ZO-1, Occludin, Claudin-1, and Claudin-8 via p38 MAPK and ERK1/2 activation.
ZO-1↑,
OCLN↑,
CLDN1↑,
IBI↑, fucoidan supplementation improves intestinal barrier function by enhancing intestinal microbiota diversity
GutMicro↑,
NK cell↑, ↑NK cell-mediated anticancer immunity
STAT3↓, Inhibits STAT3 Signaling
eff↑, Astragalus polysaccharide as a topical mucosal adjuvant to boost the anticancer efficacy of immune checkpoint inhibitors

7861- isoO,    Isoorientin Inhibits Inflammation in Macrophages and Endotoxemia Mice by Regulating Glycogen Synthase Kinase 3 β
- vitro+vivo, Nor, RAW264.7
*Inflam↓, Isoorientin has anti-inflammatory effects; however, the mechanism remains unclear.
*GSK‐3β↓, isoorientin is an inhibitor of glycogen synthase kinase 3β (GSK3β) in vitro
*TNF-α↓, isoorientin decreased the production of TNF-α, IL-6, and IL-1β and increased the expression of p-GSK3β in vitro and in vivo, similar to LiCl.
*IL6↓,
*IL1β↓,
*p‑GSK‐3β↑,
*eff↑, Coadministration of isoorientin and LiCl showed antagonistic effects
*COX2/PTGS2↓, Isoorientin decreased the expression of COX-2, inhibited the activation of ERK and NF-κB, and increased the activation of Nrf2/HO-1 in LPS-induced RAW264.7 cells
*ERK↓,
*NF-kB↓,
*NRF2↑,
*HO-1↑,
*OCLN↑, Isoorientin increased the expressions of occludin and ZO-1 in the brain of endotoxemia mice.
*ZO-1↑,
*BBB↝, protect the integrity of the blood-brain barrier and the homeostasis in the brain.

5934- TV,    Protective Effects of Natural Antioxidants on Inflammatory Bowel Disease: Thymol and Its Pharmacological Properties
- Review, Var, NA
*Inflam↓, anti-inflammation, anti-oxidation, anti-bacteria, anti-fungal, and anti-tumor potential
*antiOx↑,
*Bacteria↓,
AntiTum↑,
*toxicity∅, A high dose of thymol up to 500 mg/kg diet has been shown to have no toxicity
*IBI↑, thymol improves intestinal integrity and alleviates intestinal injury via the regulation of the immune response and oxidation-reduction homeostasis
*ZO-1↑, increasing the expression of the tight junction protein zonula occludens-1 (ZO-1) and occludins
*OCLN↑,
*COX1↑, up-regulates cyclooxygenase-1 (COX1) activity
*TLR4↓, thymol inhibits TLR4 expression and then inhibits the activation of NF-κB signaling, which reduces the production of inflammatory cytokines, such as TNF-α and IL-1β [58,59]
*NF-kB↓,
*TNF-α↓,
*IL1β↓,
*TAC↑, Thymol Improves Anti-Oxidant Capacity in IBD
*NRF2↑, Studies have indicated that thymol activates Nrf2 signaling in different tissues
*GutMicro↑, Thymol Changes Gut Microbes and Prevents Pathogen Infection. thymol also promoted the colonization of beneficial bacteria, such as Clostridium, Lactobacillus, and Bacteroides, to improve gut health

5935- TV,  CAR,    Effects of thymol and carvacrol supplementation on intestinal integrity and immune responses of broiler chickens challenged with Clostridium perfringens
- in-vivo, Nor, NA
*Dose↝, EO, which contained 25 % thymol and 25 % carvacrol as active components. (0, 60, 120, or 240 mg/kg)
*OCLN↑, occludin gene expression tended to be up-regulated linearly with increasing EO dosages
*TLR2↓, linearly inhibited the mRNA expression of TLR2 and tumor necrotic factor-α in the ileum
*TNF-α↓,
Bacteria↓, The beneficial effects of EO on intestinal lesions and histomorphology might be associated with their antibacterial activity and stabilizing effects on intestinal microflora
GutMicro↑,


Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

GSH↓, 1,   ROS↑, 1,   ROS⇅, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   Bax:Bcl2↑, 1,   Casp3↑, 1,   Casp7↑, 1,   MAPK↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   PI3K↓, 1,   STAT3↓, 1,  

Migration(tgid=13) ⓘ

CLDN1↑, 1,   MMPs↓, 1,   TJ↑, 1,   TumCP↓, 1,   TumMeta↓, 1,   ZO-1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

IBI↑, 1,   OCLN↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   NK cell↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

ADAM10?, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 2,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

GutMicro↑, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   antiNeop↑, 1,   AntiTum↑, 1,   Risk↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 35

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 3,   GPx↑, 1,   GSH↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   NRF2↑, 2,   ROS↓, 1,   SOD↑, 1,   TAC↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

LDL↓, 1,  

Cell Death(tgid=5) ⓘ

iNOS↓, 1,   iNOS↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   GSK‐3β↓, 1,   p‑GSK‐3β↑, 1,  

Migration(tgid=13) ⓘ

CLDN1↑, 1,   MUC1↑, 2,   ZO-1↑, 3,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↝, 1,   CLDN3↑, 1,   IBI↑, 3,   OCLN↑, 5,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↑, 1,   COX2/PTGS2↓, 2,   ICAM-1↓, 1,   IFN-γ↓, 1,   IL1β↓, 3,   IL6↓, 3,   Imm⇅, 1,   Inflam↓, 4,   NF-kB↓, 3,   PGE2↓, 1,   TLR2↓, 1,   TLR4↓, 2,   TNF-α↓, 4,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 1,   BDNF↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

GutMicro↑, 2,   IL6↓, 3,   TG/TAG↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 1,   toxicity↓, 1,   toxicity∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 1,   Bacteria↓, 1,  
Total Targets: 52

Scientific Paper Hit Count for: OCLN, Occludin
2 Carvacrol
2 Thymol-Thymus vulgaris
1 Cynara scolymus/Globe Artichoke/Artichoke Extract
1 Fucoidan
1 isoorientin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1463  State#:%  Dir#:2
  wNotes=on  sortOrder:rid,rpid

 

Home Page